Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...